CLSA Premium Limited provided consolidated earnings guidance for the year ended 31 December 2023. For the year, the company expects the Group to record a consolidated net profit of approximately HKD 7.7 million, as compared with the audited consolidated net loss of approximately HKD 31.1 million for the year ended 31 December 2022. The expected net profit was mainly attributable to the significant growth of healthcare business in the year 2023 with revenue from sales of healthcare products exceeding 3 times that of year 2022.